new sale driver focu
sale y/i ahead januari pre-
announc our/street origin oper
margin well ahead versu origin solid sg leverag
better gm sale guidanc reiter
continu leverag expect despit new dtc continu invest
competit dynam continu bear watch near-term tailwind
recent medicar launch solid intern expans look ahead type
penetr increasingli look promis dtc expect roll pump
partner launch build on-track full roll-out believ
drive market expans share gain
us/ou revenu exceed
medicar dme pharmaci channel management highlight strong launch
direct market germani uk well distributor market launch
e-commerc platform canada also increment driver
guidanc sale guidanc repres growth
y/i sale growth guidanc build pt revenue-per-pati
headwind channel expans effort medicare/ mix
believ manag factor increment pressur us
time remain uncertain forecast non-gaap oper margin expans
target despit expect dtc invest
management re-affirmed full roll-out limit launch expect late near-
term focu clinic trial initi scale-up manufactur
significantli downsiz low-cost dispos design provid benefit
current focus market open big new market start
non-intens system design icgm complianc
file japan anticip approv reimburs
coverag time tbd manag expect doubl capac mid-year
enabl aggress dtc particularli direct toward medicar patient
expect begin effort build includ grow
intensive-insulin coverag non-intens data includ progress
estim sale estim rise
us/ou sale rise
ep rise higher sales/oper
leverag lower tax ou expans potenti upsid driver higher
estim peer multipl expans pt rise
year price histori
medic devic
compani focus design
develop continu glucos
monitor system diabet patient
lead product cgm
analyst certif import disclosur see disclosur
cgm penetr type diabet reach long-term
assum us growth market channel
expans well medicar contribut off-set lower revenue-p
-patient/potenti dtc potenti upsid
increment non-intens benefit built conserv
increment contribut built point
greater volum acceler pharmaci access
type contribut sale beyond current modest current
under-penetrated patient popul robust pipelin
forecast strong sale growth next sever year
competit remain high particularli libr
launch new market
mileston toward full launch
launch hybrid closed-loop system pump partner
competitor launch lead greater market share loss
price target driven blend discount cash flow assum weight averag cost capit
termin growth rate base estim ebitda price target impli ev/sal multipl
in-lin peer current year multipl
risk includ competit slowdown revenu due macroeconom pressur clinic trial fda risk
stock price compani mention report
